ALKS Insider Trading

Insider Ownership Percentage: 4.40%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $12,938,532.90

Alkermes Insider Trading History Chart

This chart shows the insider buying and selling history at Alkermes by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$5M$0$5MTotal Insider BuyingTotal Insider Selling

Alkermes Share Price & Price History

Current Price: $27.91
Price Change: Price Increase of +0.07 (0.25%)
As of 04/28/2025 05:00 PM ET

This chart shows the closing price history over time for ALKS up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
JunJulAugSepOctNovDecJanFebMarApr$27.91Closing price on 04/28/25:

SEC Filings (Institutional Ownership Changes) for Alkermes (NASDAQ:ALKS)

95.21% of Alkermes stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at ALKS by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$9.33Mbought$3.35MsoldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$400M-$200M$0$200M$400MTotal InflowsTotal Outflows
Alkermes logo
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Read More on Alkermes

Today's Range

Now: $27.91
Low: $27.61
High: $28.28

50 Day Range

MA: $31.76
Low: $26.59
High: $35.52

52 Week Range

Now: $27.91
Low: $22.90
High: $36.45

Volume

1,517,298 shs

Average Volume

1,751,297 shs

Market Capitalization

$4.60 billion

P/E Ratio

12.86

Dividend Yield

N/A

Beta

0.39

Who are the company insiders with the largest holdings of Alkermes?

Alkermes' top insider investors include:
  1. Craig C Hopkinson (EVP)
  2. Christian Todd Nichols (SVP)
  3. Cato T Laurencin (Director)
  4. Nancy Wysenski (Director)
Learn More about top insider investors at Alkermes.

Who are the major institutional investors of Alkermes?

Alkermes' top institutional shareholders include:
  1. Principal Financial Group Inc. — 0.56%
  2. Rhumbline Advisers — 0.28%
  3. GAMMA Investing LLC — 0.11%
  4. Wedge Capital Management L L P NC — 0.07%
  5. State of Alaska Department of Revenue — 0.05%
  6. New York State Teachers Retirement System — 0.05%
Learn More about top institutional investors of Alkermes stock.

Which institutional investors are selling Alkermes stock?

During the last quarter, ALKS stock was sold by these institutional investors:
  1. Robeco Institutional Asset Management B.V.
  2. Allspring Global Investments Holdings LLC
  3. Assenagon Asset Management S.A.
  4. Rhumbline Advisers
  5. Vontobel Holding Ltd.
  6. Exchange Traded Concepts LLC
  7. Teacher Retirement System of Texas
  8. Wealth Enhancement Advisory Services LLC
Within the last year, company insiders that have sold Alkermes company stock include:
  1. Craig C Hopkinson (EVP)
  2. Christian Todd Nichols (SVP)
  3. Cato T Laurencin (Director)
Learn More investors selling Alkermes stock.

Which institutional investors are buying Alkermes stock?

During the last quarter, ALKS stock was purchased by institutional investors including:
  1. GAMMA Investing LLC
  2. Advisor Resource Council
  3. Principal Financial Group Inc.
  4. Private Client Services LLC
  5. Ritholtz Wealth Management
  6. Avanza Fonder AB
  7. Pallas Capital Advisors LLC
  8. Wedge Capital Management L L P NC